All three companies are early-stage biotechnology companies working on next-generation therapeutics with advanced ...
Pluvicto, Novartis’ blockbuster radiopharmaceutical for prostate cancer, has been greenlighted by the FDA for use earlier in ...
Congress Wealth Management LLC DE purchased a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) in the 4th ...
Corient Private Wealth LLC lessened its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 4.0% during the ...
Multinationals with significant operational footprints in Ireland, Germany, and Switzerland could bear the brunt of the Trump ...
After a 6-year run, CRISPR Therapeutics COO Julianne Bruno is stepping out the door to pursue other opportunities. Bruno's ...
What’s really exciting about gene editing is precision and speed, says Pairwise cofounder and CEO Tom Adams, PhD.
Spread the love Introduction The biotechnology industry continues to be at the forefront of scientific innovation, driving ...
4d
Zacks Investment Research on MSNPromising Genomics & Synthetic Biology Stocks to Consider in 2025Genomics encompasses the study of a complete set of genes, their work process, and their way of interacting with each other and the environment. While it incorporates elements of genetics, the primary ...
CRISPR Therapeutics’ Julianne Bruno is hitting the exit in favor of external opportunities, marking the latest shakeup to the ...
Learn more about whether Alvotech or CRISPR Therapeutics AG is a better investment based on AAII's A+ Investor grades, which ...
Epicrispr Biotechnologies to Begin Clinical Trials for its Lead Epigenetic Therapy for FSHD Patients
The therapy, EPI-321, is intended to treat cases of facioscapulohumeral muscular dystrophy, a genetic neuromuscular disorder.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results